Kornimate/medical-research-clean huggingface dataset:
modified diagnosis and treatment of neonatal hemolysis with etcoc in snh

Conditions: Neonatal Hyperbilirubinemia

Summary: the goal of this clinical trial is to learn if modified diagnosis and treatment (mdt) of neonatal hemolysis (a common cause to newborn jaundice) incorporated with etcoc measurement (a non-invasive measurement of exhaled gas) works to prevent brain damage in newborns with severe hyperbilirubinemia (snh). it will also learn about the. occurrence of cranial mri in the study participants. the main questions it aims to answer are: * does mdt lower the possibilities participants have brain damage before the age of one? * how many times of abnormalities in cranial mri is detected before the age of one? researchers will compare mdt to a control (a current management) to see if mdt works to prevent brain damage in newborns with shn. participants will: * take mdt or a control method in the management of snh * assess if there's brain damage before discharge and at the year of one * record how many times of abnormalities in cranial mri is detected before the age of one


Eligibility criteria:
inclusion criteria: inclusion criteria: infants with gestational age of 35(+0) to 41(+6) weeks and birth weight ≥ 2500 grams * infants with severe neonatal hyperbilirubinemia, including those whose serum total * bilirubin (tsb) levels reach above 20 mg/dl or whose tsb levels at any time reach within 2 mg/dl of the exchange transfusion threshold (i.e., tsb \> (threshold - 2) mg/dl). exclusion criteria: * infants with definite congenital genetic metabolic diseases, chromosomal or genetic disorders, or severe malformations.

Keywords: etcoc neonatal hemolysis neonatal hyperbilirubinemia modified
preg - offspring: investigation of children from mothers with and without gestational diabetes

Conditions: Offspring Exposed to GDM and Control

Summary: gestational diabetes is the most common complication during pregrancy. with a screening between week 24 and 28 of gestation women with gestational diabetes can be identified and treated. treatment comprises modification of diet and in some cases taking medication. this treatment lowers undesirable events like macrosomia or premature birth. however, unitl gestational diabetes is diagnosed the fetus is exposed to increased intrauterine glucose levels. the long-term effects of a well-managed gestational diabetes on the development of the offspring is still not well understood. therefore, the preg - offspring study investigates several aspects of development in children from healthy and gestational diabetes mothers until adulthood.


Eligibility criteria:
inclusion criteria: * signed informed consent provided by child and parent * documented oral glucose tolerance test of the mother during pregnancy * adequate management of gestational diabetes until birth exclusion criteria: * severe malformation that makes an examination impossible * existent of coagulation disorder with increased risk of bleeding after blood sampling
the effect of application of proximal and distal upper rehabilitation robot with stroke patients

Conditions: Stroke

Summary: comparison of the effect of upper limb rehabilitation on the application of proximal upper rehabilitation robot and distal upper rehabilitation robot with stroke patients


Eligibility criteria:
inclusion criteria: * hemiplegic patients secondary to first cerebrovascular accidents * onset ≥ 3 months * 29 ≤ fugl-meyer assessment score * cognitively intact enough to understand and follow the instructions from the investigator exclusion criteria: * history of surgery of affected upper limb * fracture of affected upper limb

Keywords: upper limb rehabilitation stroke proximal upper rehabilitation robot distal upper rehabilitation robot
hyponatremia volume status analysis by point-of-care ultrasound

Conditions: Hyponatremia; Water-Electrolyte Imbalance

Summary: this observational study aims to analyze the time of correction of hyponatremia in patients within an internal medicine ward. the researchers will assess volume status using both clinical evaluation and point-of-care ultrasound. patients will be categorized based on whether they have the same volume status determined clinically and by ultrasound or a different status between the two methods. by tracking sodium levels daily until normalization, the study will compare the time of hyponatremia correction between the two groups.

the main question it aims to answer are what is the time of correction of hyponatremia by assessing the volume status clinically or by point of care of ultrasound?. participants will be asked to participate in the study and they will be receive a volume status by a portable ultrasound. if they have the same volume status clinically and by point of care ultrasound they will be referred as group 1. if they have a different volume status clinically or by point of care ultrasound they will be referred as group 2. researchers will follow the patients by measuring the sodium levels daily until they reach normal sodium levels ( \>135meq/l) and will compare group 1 and group 2 with a survival analysis.

Eligibility criteria:
inclusion criteria: * age greater or equal to 18 years * hypotonic hyponatremia (less than 275mosm/kg) calculated by the following formula (2 na+glucose/ 18) exclusion criteria: * patients who are critically ill with ventilatory support. * patients with clinical signs suggestive of hypovolemia and have a documented history of aortic insufficiency or show mitral insufficiency during pocus (point-of-care ultrasound).

Keywords: hyponatremia water-electrolyte imbalance pocus point-of-care ultrasound
all-sct bfm international- hsct in children and adolescents with all

Conditions: Lymphoblastic Leukemia, Acute, Childhood;

Summary: with this protocol the all-sct bfm international study group wants * to evaluate whether hematopoietic stem cell transplantation (hsct) from matched family or unrelated donors (md) is equivalent to the hsct from matched sibling donors (msd). * to evaluate the efficacy of hematopoietic stem cell transplantation (hsct)from mismatched family or unrelated donors (mmd) as compared to hsct from matched sibling donors or matched donors. * to determine whether therapy has been carried out according to the main hsct protocol recommendations. the standardisation of the treatment options during hsct from different donor types aims at the achievement of an optimal comparison of survival after hsct with survival after chemotherapy only. * to prospectively evaluate and compare the incidence of acute and chronic graft-versus-host-disease (gvhd) after hsct from matched sibling donor (msd), from matched donor (md) and from mismatched donor (mmd).

patients with high risk or relapsed acute lymphoblastic leukaemia (all) have a worse prognosis compared to all other patients with all. for these patients additional therapy approaches are required after they have achieved remission with multimodal chemotherapy. allogeneic haematopoetic stem cell transplantation shows promising results mainly due to an immunological antileukaemic control by the graft-versus-leukaemia effect but treatment related mortality and morbidity remains a serious problem.

Eligibility criteria:
inclusion criteria: * age at time of initial diagnosis or relapse diagnosis, respectively under or equal 18 years * indication for allogeneic hematopoietic stem cell transplantation(hsct) * complete remission before hematopoietic stem cell transplantation (hsct) * written consent of the parents (legal guardian) and, if necessary, the minor patient via informed consent form * no pregnancy * no secondary malignancy * no previous hematopoietic stem cell transplantation (hsct) * hematopoietic stem cell transplantation (hsct) is performed in a study participating centre. exclusion criteria: * age at time of initial diagnosis or relapse diagnosis, respectively above 18 years * no indication for allogeneic hsct * no complete remission before sct * no written consent of the parents (legal guardian) and, if necessary, the minor patient via informed consent form * pregnancy * secondary malignancy * previous hsct * hsct is not performed in a study participating centre.

Keywords: all hsct children adolescents
effects of lysozyme on acute exacerbation of chronic obstructive pulmonary disease : a randomised placebo-controlled study

Conditions: COPD

Summary: the aim of this study is to assess the effectiveness in preventing exacerbation of 52 weeks lysozyme administration in patients with copd.


Eligibility criteria:
inclusion criteria; * patients were eligible for inclusion in the study if they were over 20 years of age and below 85 years of age, and had a smoking history, a diagnosis of copd, a ratio of fev1 to forced vital capacity(fvc) of less than 70%, and a documented history of at least one exacerbation leading to any treatment within the previous year. exclusion criteria; * patients with egg allergy * patients with domiciliary oxygen therapy * patients with pneumonia or pulmonary tuberculosis * patients with severe cardiovascular disorder,severe kidney disorder, severe hepatic disorder, severe hematological disorder. * patients with cancer.

Keywords: lysozyme hydrochloride copd
novel form of acquired long qt syndrome

Conditions: Long QT Syndrome; Connective Tissue Diseases; Rheumatoid Arthritis

Summary: the goal of this study is to determine whether anti-ro/ssa antibodies are associated with acquired qt prolongation in subjects with connective tissue disease. the investigators will investigate whether gender or race influence correlation between anti-ro antibody status and prolonged qt interval and the role of inflammatory cytokines in association with anti-ro antibodies and qt prolongation. the investigators propose to add an additional objective to test whether qt prolongation is reversible with moderate doses of prednisone in patients with qt interval greater than 500 msec.

there are two parts to this study. first, the investigators propose a prospective, observational study of subjects with connective tissue disease (ctd). data on ctd diagnosis, disease activity, medications, electrolytes, anti-ro ab status, qt interval and serum for measurement of inflammatory markers and cytokines will be collected. please see the research strategy for details of the protocol. the investigators expect that qtc prolongation will have a positive correlation with anti-ro ab positivity, elevated measures of inflammatory markers and higher levels of inflammatory cytokines, especially il-6. the second part of the study will include a subgroup of subjects who have qtc prolongation of more than 500 milliseconds. this is a proof of concept study to investigate whether immunosuppressive treatment with moderate dose of prednisone will reduce qtc in ctd patients exhibiting an excessive qtc prolongation of \>500msec. patients enrolled in the prospective observational study with qtc prolongation of more than 500 msec will receive oral prednisone 40mg daily for 3 days followed by 20mg for eleven days (a total of 2 weeks) with the goal to shorten or normalize the prolonged qtc. other factors that may cause prolonged qtc will be evaluated and corrected as needed. inflammatory markers, cytokines, and qtc will be measured at baseline and serially at days 3 and 14 (end of treatment). the investigators will monitor changes in qtc during three 24-hour periods during treatment at baseline, day 3 and day 14. risks of prednisone include elevated serum glucose levels, edema, increased risk of infection and blood pressure elevation. the dosage and duration of prednisone used in this study is similar to that given for a severe allergic reaction. the pi will monitor the patients for potential side effects which will immediately be addressed.

Eligibility criteria:
inclusion criteria: - patients enrolled in new york harbor healthcare system with connective tissue disease exclusion criteria: * atrial fibrillation * intraventricular conduction delay with wide qrs complex * acute medical conditions * drug overdose * hypothermia * known diagnosis or family history of hereditary long qt syndrome, complete bundle brunch block, ventricular paced rhythm, profound bradycardia and tachycardia, and uncorrected hypothyroidism

Keywords: cytokines
cerebral reorganization in schizophrenia

Conditions: Schizophrenia

Summary: the purpose of this study is to reveal the specific effects of computer-aided cognitive training on cerebral reorganization in schizophrenia

impairment in cognitive functions is one of the main symptoms in schizophrenia and is currently one of the challenges in the treatment of the disease. in this study we compare effects of two computer-aided training programs. one focused on auditory perception and processing as a basic ability underlying higher order information processing. the other training focus on facial affect discrimination and working memory. both trainings are computer-aided and time-intensive, including up to twenty sessions within four weeks.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of schizophrenia and disorders with psychotic features * intact auditory perception * intact visual perception exclusion criteria: * mental retardation * age over 60 * insufficient german language knowledge

Keywords: cognitive training neuroplasticity meg matrics
assessment of csf shunt flow and headaches with a thermal measurement device

Conditions: Hydrocephalus

Summary: this study evaluates the performance of a device for non-invasively assessing cerebrospinal fluid (csf) shunt flow over multiple measurements performed by a study subject during headache and non-headache periods.


Eligibility criteria:
inclusion criteria: 1. existing ventriculoperitoneal csf shunt 2. subject experiencing ongoing headaches including at least 15 headache days per month for the past 3 months 3. region of intact skin overlying an unambiguously identifiable palpable chronically indwelling ventricular shunt which crosses the clavicle and is appropriate in size for application of the study device 4. available for remote and in-person follow-up during the 30-day measurement period 5. signed informed consent by subject or a parent, legal guardian, health care agent, or surrogate decision maker (according to local statutes) 6. subject or caregiver is able to clearly communicate and document information and shunt symptoms in english 7. subject is at least 6 years old but not more than 80 years old exclusion criteria: 1. presence of more than one distal shunt catheter in the study device measurement region 2. shunt is not palpable due to depth or depth of shunt where the device will be placed is greater than 4 mm per ultrasound evaluation 3. presence of an interfering open wound or edema in the study device measurement region 4. subject-reported history of serious adverse skin reactions to silicone-based adhesives 5. investigator judges that the subject is likely to be lost to follow-up due to unavailability or clinical outcome being unobtainable 6. investigator judges that the subject is unlikely to successfully take reliable measurements at home 7. investigator judges that the subject/subject's caretaker would not be able to successfully place the device without assistance 8. use of the study device would interfere with standard patient care, or emergency surgery that cannot be delayed, or participation in the study will interfere with, or be detrimental to, administration of optimal healthcare to the subject 9. prior enrollment in this study 10. participation in any other investigational procedural, pharmaceutical, and/or device study that may influence the collection of valid data under this study
gore embolic protection with reverse flow

Conditions: Carotid Artery Stenosis

Summary: to compare the 30-day safety and efficacy of the gore flow reversal system when used with approved carotid stents to an objective performance criterion derived from distal embolic protection studies.

the gore flow reversal system, manufactured by w. l. gore \& associates, inc., was developed as a proximal occlusion device to reverse the flow of blood in the carotid artery. it is designed to achieve embolic protection prior to crossing the lesion in the majority of cases in order to minimize the possibility of an adverse event occurrence. the objective of this study is to assess the safety and effectiveness of the gore flow reversal system when used to provide embolic protection during carotid artery stent (cas) procedures. subjects diagnosed with carotid stenosis requiring revascularization and are at high risk for adverse events from cea are eligible to participate.

Eligibility criteria:
inclusion criteria: * carotid stenosis requiring revascularization and indicating either symptomatic status, with carotid stenosis ≥ 50% or asymptomatic status with carotid stenosis ≥ 80% * target lesion is located in one of the following:(a) internal carotid artery (ica) (b) bifurcation (c) common carotid artery (cca) proximal to the bifurcation * at anatomic risk for adverse events from cea (e.g. restenosis after a prior cea) or at co-morbid risk for adverse events from cea (e.g., unstable angina with ecg changes) exclusion criteria: * recent surgical procedure within 30 days before or after the stent procedure * uncontrolled sensitivity to contrast media * renal insufficiency * recent evolving, acute stroke within 21 days of study evaluation * myocardial infarction within 72 hours prior to stent procedure * history of a prior major ipsilateral stroke with residual neurological deficits likely to confound the neurological assessments (e.g., nihss) * neurological deficits not due to stroke likely to confound the neurological assessments (e.g., nihss) angiographic exclusion criteria: * isolated ipsilateral hemisphere leading to subject intolerance to reverse flow * total occlusion of the ipsilateral carotid artery * pre-existing stent in the ipsilateral carotid artery or the contralateral carotid artery that extends into the aortic arch * presence of a filling defect, thrombus, occlusion or "string sign" in the target vessel * severe lesion calcification restricting stent deployment * carotid stenosis located distal to target stenosis that is more severe than target stenosis * \> 50% stenosis of the cca proximal to target vessel * known mobile plaque in the aortic arch

Keywords: carotid artery stenosis embolic protection device gore neuro protection system gore flow reversal system reverse flow proximal occlusion device gnps parodi empire distal embolization minimizing risks of cas paes
a clinical study of inhaled nitric oxide in moderate-to-severe chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the purpose of this study is to evaluate the influence of exercise capacity and safety of ino at doses of 10 ppm or 40 ppm for 2 hours per day after continuous treatment for one week, which is of great significance for finding safe and effective methods for treating copd.


Eligibility criteria:
inclusion criteria: 1. age ≥ 40 years, ≤ 75 years; 2. previous smoking history ≥ 10 pack-years, and had stopped smoking for one month before study entry; 3. met the diagnosis criteria of moderate and severe copd: a post-bronchodilator fev1/fvc \< 0.7, and 30%\< fev1 \< 80% predicted; 4. signed informed consent and performed all the study mandated procedures. exclusion criteria: 1. pregnant or lactating women; 2. current or recent month user of nicotine-like substances (including nicotine patches, etc.); 3. a diagnosis of asthma or other non-copd respiratory disease, in the opinion of the investigator; 4. lack of patency of nares upon physical examination; 5. experienced during the last month an exacerbation requiring start of or increase in systemic oral corticosteroid therapy; 6. left ventricular systolic dysfunction: left ventricular ejection fraction (lvef) \< 50%; 7. clinically significant valvular heart disease, including aortic valvular disease (moderate or severe aortic stenosis or regurgitation) and/or mitral valve disease (moderate or severe mitral stenosis or regurgitation), or status post mitral valve replacement; 8. use within 30 days of screening or current use of approved pulmonary hypertension medications such as sildenafil, bosentan or prostacyclines; 9. use of investigational drugs or devices within 30 days prior to enrollment into the study; 10. any underlying medical or psychiatric condition that, in the opinion of the investigator, makes the subject an unsuitable candidate for the study.
regulation of bone formation in renal osteodystrophy

Conditions: Secondary Hyperparathyroidism; Renal Osteodystrophy

Summary: to examine the effects of two types of active vitamin d (calcitriol and doxercalciferol) and two phosphate binders (sevelamer and calcium carbonate) on the bone disease and blood tests of children with kidney failure

pediatric patients treated with ccpd who displayed biochemical and bone biopsy proven secondary hyperparathyroidism were randomly assigned to one of 2 vitamin d analogues (calcitriol or doxercalciferol) and one of two phosphate binders (sevelamer or calcium carbonate) in a two by two factorial designed prospective trial. serum biochemical measurements were obtained at baseline and monthly throughout the 8 months of the trial. bone biopsy was obtaine at baseline and repeated at study completion.

Eligibility criteria:
inclusion criteria: * stable end-stage kidney disease treated with continuous cycling peritoneal dialysis, * biochemical evidence of secondary hyperparathyroidism (pth\>400 pg/ml) with bone biopsy evidence of high turnover bone disease exclusion criteria: * history of parathyroidectomy * growth hormone * prednisone, or other immunosuppressant medication within the past year. * recent history of medication non-compliance.
mirabegron for female oab patients: comparison of daytime and nighttime dosing

Conditions: Overactive Bladder Syndrome

Summary: the aim of this study is to elucidate whether night-time dosing of mirebegron can improve nocturia, compared with daytime dosing of mirabegron.

background/purpose: women with overactive bladder syndrome (oab) may have symptoms of nocturia, in addition to urgency and frequency. women with nocturia are prone to suffer from a fall and fracture. beta-3 agonist is an effective treatment for oab. however, women with nocturia may need adjuvant desmopressin to improve nocturia. the aim of this study is to elucidate whether night-time dosing can improve nocturia, compared with daytime dosing. patients and methods: the investigators will perform a prospective randomized controlled trial to recruit 90 female oab patients at the outpatient clinic of department of obstetrics and gynecology of far eastern memorial hospital. all oab women will be treated by mirabegron. all enrolled oab women will be allocated to two groups (group a and b). the women in group a will receive daytime dosing of mirabegron treatment; and the women in group b will receive nighttime dosing of mirabegron. all oab female patients will be asked to complete urgency severity scales, overactive bladder symptoms scores questionnaires, king's health questionnaires, 3-day bladder diary before, 4 weeks' and after 12 weeks' mirabegron treatment. stata software is used for statistical analyses. possible results: the investigators can answer whether night-time dosing of mirabegron can improve nocturia, compared with daytime dosing.

Eligibility criteria:
inclusion criteria: * oab symptoms for at least one month * \>20 years exclusion criteria: * allergy to mirabegron, urinary tract infections, unstable hypertension